VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ALXO
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ALXOALX Oncology Holdings Inc.
$0.97$131M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
ALXO logo

ALX Oncology Holdings Inc.

ALXO
NASDAQ · Oncology Biotech
$0.97
At close - Nov 18, 4:00 PM EST - USD
Market Cap$131M
P/E-1.7x
52W High$2.66
Volume562.47K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q2

Pre-Revenue Biotech Burning Cash Against Thin Liquidity Buffer

ALX Oncology remains a pre-revenue clinical-stage biotech, with no reported revenue across the ten quarters analyzed and quarterly R&D cut from $34.7M in 2024Q2 to $13.1M in 2026Q2, a reduction of roughly 62 percent that has narrowed the operating loss from -$41.5M to -$18.0M.

GrowthMixed
ProfitabilityNegative
ValuationReview
TechnicalsWeak
Explore valuation models
MARKET ACTION

ALXO price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

5/12 Beats

EPS beat 5 of last 12 quarters

02

Valuation risk

-106% Peers

P/E is 106% below peer median

03

Market leadership

RS 15 · Lag

Laggard (Underperforming 85% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 16

Market performance

Price History →

Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
ALXO-15.64%
S&P 500 (^GSPC)+6.88%
1-Year Return
ALXO-40.48%
S&P 500 (^GSPC)+10.62%
3-Year Return
ALXO-90.10%
S&P 500 (^GSPC)+56.52%
5-Year Return
ALXO-97.64%
S&P 500 (^GSPC)+55.82%

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
-
Net income FY25
-$102M+24.6% YoY
Free cash flow FY25
-$84M+31.1% YoY
Operating margin FY25
-
ROIC (FY25)-122%
Avg ROIC 5Y-10175.7%
ROE (TTM)-73.4%
Piotroski Score2 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate5/12 (42%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 16, 2026
-$0.15+0.0%
vs -$0.15
—
vs —
Q3 2026
Aug 6, 2026
-$0.13+9.0%
vs -$0.14
—
vs —
Q2 2026
May 8, 2026
-$0.17-13.3%
vs -$0.15
—
vs —
Q1 2026
Feb 27, 2026
-$0.42-10.5%
vs -$0.38
—
vs —
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Seeking Alpha·1d ago
ALX Oncology Holdings Inc. (ALXO) Presents at UBS Global Biopharma Conference 2026 Transcript

ALX Oncology Holdings Inc. (ALXO) Presents at UBS Global Biopharma Conference 2026 Transcript

GlobeNewsWire·2d ago
ALX Oncology Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Expect to report safety and early efficacy data from the Phase 1 dose-escalation study of ALX2004 in EGFR-expressing solid tumors and plan to host a KOL webinar to review the results in December 2026 Topline data from 120 patients in Phase 2 ASPEN-09-Breast clinical trial evaluating evorpacept in combination with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer expected in 2H 2027 SOUTH SAN FRANCISCO, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology," Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update.

GlobeNewsWire·Nov 10, 2026
ALX Oncology to Present at Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that ALX Oncology leadership will participate in fireside chats at three upcoming investor conferences.

GlobeNewsWire·Sep 28, 2026
ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer

Achieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for control, with response rates increasing to 63.6% versus 23.1% among patients with high CD47 expression and retained HER2-positive disease

Filtered for ALX Oncology Holdings Inc.More Headlines
04

Compare before deciding

Benchmark ALXO against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for ALX Oncology Holdings Inc. (ALXO)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
ALXO logoALXOALX Oncology Holdings Inc.Current
$0.97$130.54M-1.70——-73.35%—
FATE logoFATEFate Therapeutics, Inc.
$1.05$122.39M-1.04-51.24%-2619.64%-73.92%—
IMVT logoIMVTImmunovant, Inc.
$33.17$6.85B-13.47—-7173.52%-63.01%—
RCUS logoRCUSArcus Biosciences, Inc.
$15.76$1.98B-4.51-4.26%-445%-90.04%—
AGEN logoAGENAgenus Inc.
$6.40$266.51M18.9710.37%20.98%——
NKTR logoNKTRNektar Therapeutics
$34.42$1.18B-6.64-43.89%-339.67%-29.31%—

Compare ALXO vs Peers

ALX Oncology Holdings Inc. (ALXO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs FATE

Most directly comparable listed peer for ALXO.

Scale Benchmark

vs AMGN

Larger-name benchmark to compare ALXO against a more recognizable public peer.

Peer Set

Compare Top 5

vs FATE, IMVT, RCUS, AGEN

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

ALXO SEC Filings & Documents

ALX Oncology Holdings Inc. (ALXO) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Aug 6, 2026·SEC

Material company update

Jun 30, 2026·SEC

Material company update

Jun 26, 2026·SEC

10-K Annual Reports

3
FY 2026

Mar 9, 2026·SEC

FY 2025

Mar 6, 2025·SEC

FY 2024

Mar 7, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Aug 6, 2026·SEC

FY 2026

May 8, 2026·SEC

FY 2025

Nov 7, 2025·SEC

Get notified when ALXO posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

ALXO Frequently Asked Questions

ALX Oncology Holdings Inc. (ALXO) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
Is ALXO profitable?

No. ALX Oncology Holdings Inc. (ALXO) reported a net loss of $80.6M over the trailing twelve months.

Dividend & Returns
What is ALXO's return on equity?

ALX Oncology Holdings Inc. (ALXO) had a return on equity (ROE) of -73.4% over the trailing twelve months. A negative ROE means the company lost money over the period.

What is ALX Oncology Holdings Inc.'s free cash flow?

ALX Oncology Holdings Inc. (ALXO) had negative free cash flow of $68.6M over the trailing twelve months.

What if you invested $1,000 in ALXO back in 2018?

Total return calculator · dividends reinvested · 8+ years of data

See returns →